NDC 59353-120

RETACRIT

Epoetin Alfa-epbx

RETACRIT is a Intravenous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Vifor (international) Inc.. The primary component is Erythropoietin.

Product ID59353-120_4debf86d-aec2-49c4-b454-6ad4b4f7b9b5
NDC59353-120
Product TypeHuman Prescription Drug
Proprietary NameRETACRIT
Generic NameEpoetin Alfa-epbx
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS; SUBCUTANEOUS
Marketing Start Date2020-09-11
Marketing CategoryBLA / BLA
Application NumberBLA125545
Labeler NameVifor (International) Inc.
Substance NameERYTHROPOIETIN
Active Ingredient Strength20000 [iU]/mL
Pharm ClassesErythropoiesis-stimulating Agent [EPC],Erythropoietin [CS],Increased Erythroid Cell Production [PE]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 59353-120-10

10 VIAL, MULTI-DOSE in 1 CARTON (59353-120-10) > 1 mL in 1 VIAL, MULTI-DOSE (59353-120-01)
Marketing Start Date2020-11-09
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "RETACRIT" or generic name "Epoetin Alfa-epbx"

NDCBrand NameGeneric Name
0069-1305RETACRITepoetin alfa-epbx
0069-1306RETACRITepoetin alfa-epbx
0069-1307RETACRITepoetin alfa-epbx
0069-1308RETACRITepoetin alfa-epbx
0069-1309RETACRITepoetin alfa-epbx
0069-1311RETACRITepoetin alfa-epbx
0069-1318RETACRITepoetin alfa-epbx
59353-004RETACRITRETACRIT
59353-002RETACRITRETACRIT
59353-003RETACRITRETACRIT
59353-010RETACRITRETACRIT
59353-120RETACRITRETACRIT
59353-220RETACRITRETACRIT

Trademark Results [RETACRIT]

Mark Image

Registration | Serial
Company
Trademark
Application Date
RETACRIT
RETACRIT
87340145 5770173 Live/Registered
Hospira, Inc.
2017-02-17
RETACRIT
RETACRIT
85028565 3925022 Dead/Cancelled
Hospira, Inc.
2010-05-03
RETACRIT
RETACRIT
77117569 not registered Dead/Abandoned
Hospira, Inc.
2007-02-27

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.